During the past decade, Gunma Prefectural Cancer Center conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 7 clinical trials were completed, i.e. on average, 35% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gunma Prefectural Cancer Center" #1 sponsor was "Pfizer" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Chugai Pharmaceutical" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gunma Prefectural Cancer Center" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Japan Agency for Medical Research and Development" with 1 trials as a collaborator and "Japan Clinical Oncology Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Gunma Prefectural Cancer Center" are "Breast Neoplasms" (3 trials), "Lung Cancer" (3 trials), "Epithelial Ovarian Cancer" (2 trials), "Triple-Negative Breast Cancer" (2 trials) and "Urothelial Cancer" (2 trials). Many other conditions were trialed in "Gunma Prefectural Cancer Center" in a lesser frequency.

Most popular intervention types in "Gunma Prefectural Cancer Center" are "Drug" (22 trials), "Other" (2 trials), "Procedure" (2 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Placebo" (3 trials), "Abemaciclib" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (2 trials) and "Chemotherapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Gunma Prefectural Cancer Center" are 23 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Gunma Prefectural Cancer Center". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Gunma Prefectural Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Gunma Prefectural Cancer Center, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".